- Report
- October 2024
- 193 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- September 2024
- 100 Pages
Global
From €5679EUR$5,950USD£4,758GBP
- Report
- April 2024
- 160 Pages
Global
From €4742EUR$4,969USD£3,973GBP
- Report
- September 2018
- 174 Pages
Global
From €1312EUR$1,375USD£1,099GBP
€2625EUR$2,750USD£2,199GBP
- Drug Pipelines
- July 2023
- 30 Pages
Global
From €2625EUR$2,750USD£2,199GBP
- Report
- March 2024
- 397 Pages
Global
From €7587EUR$7,950USD£6,357GBP
From €2625EUR$2,750USD£2,199GBP
- Report
- October 2023
- 145 Pages
Global
From €3006EUR$3,150USD£2,519GBP
- Report
- March 2019
- 39 Pages
Global
€9544EUR$10,000USD£7,996GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €477EUR$500USD£400GBP
Latuda is a medication used to treat mental disorders such as schizophrenia and bipolar disorder. It is a psychotropic drug, meaning it works by altering the levels of certain chemicals in the brain. It is an atypical antipsychotic, meaning it works differently than traditional antipsychotics. It is believed to work by blocking the action of dopamine, a neurotransmitter that is involved in the regulation of mood and behavior.
Latuda is a relatively new drug, having been approved by the FDA in 2010. It is available in both oral and injectable forms. It is generally well-tolerated, with few side effects. Common side effects include nausea, headache, and insomnia.
The Latuda market is a growing one, with many companies competing for market share. Some of the major players in the market include Sunovion Pharmaceuticals, Otsuka Pharmaceuticals, and Intra-Cellular Therapies. Other companies include Lundbeck, Teva Pharmaceuticals, and Mylan. Show Less Read more